Commercial Trainer, Surgical & Retina Franchises
Harrow
Summary
Owns curriculum delivery, field coaching, and certification for the Surgical and Retina sales teams. Both teams share a buy-and-bill economic model and a procedural selling motion. Counterpart to the Head, Sales—Ocular Surgery and the Head, Sales—Retina.
Job description
Position Summary
Owns curriculum delivery, field coaching, and certification for the Surgical and Retina sales teams. Both teams share a buy-and-bill economic model and a procedural selling motion. Counterpart to the Head, Sales—Ocular Surgery and the Head, Sales—Retina.
Core Responsibilities
- Deliver training and certification on ocular surgery and retina brands.
- Teach surgical and perioperative positioning, GPO-context selling, retina and in-office workflow, and biosimilar adoption.
- Ride with reps; coach district managers.
- Serve as named subject-matter verifier for procedural clinical content.
- Direct rotational Field Trainers.
Qualifications & Requirements
- Bachelor's degree; 5+ years selling buy-and-bill, surgical, or procedural products to specialists, ASCs, or hospitals.
- 1+ year in a training, field trainer, or field leadership role.
- Strong facilitation and coaching skills.
- Proficiency with AI platforms such as ChatGPT and Claude, and with Slack.
Preferred Qualifications
- Ophthalmic surgical or retina sales experience.
- Biosimilar experience.
Position Type
Remote (U.S.), field-based nationally. Travel approximately 50%.
Requirements
- Bachelor's degree
- 5+ years selling buy-and-bill, surgical, or procedural products to specialists, ASCs, or hospitals
- 1+ year in a training, field trainer, or field leadership role
- Strong facilitation and coaching skills
- Proficiency with AI platforms such as ChatGPT and Claude, and with Slack
Company overview
Harrow Health, Inc. (NASDAQ: HROW) is a publicly traded pharmaceutical company headquartered in Nashville, Tennessee, specializing in ophthalmic healthcare solutions. Founded in 2012 and formerly known as Imprimis Pharmaceuticals, the company has established itself as a growing leader in the ophthalmic pharmaceutical market. Harrow operates through multiple subsidiaries including ImprimisRx, its compounding pharmacy business that produces cGMP ophthalmic eye drops and sterile compounded products. The company's core mission focuses on providing affordable and accessible medications while maintaining an unyielding dedication to innovation. Harrow gained significant attention for developing low-cost alternatives to expensive medications, most notably creating a $1 per pill alternative to Daraprim during the Martin Shkreli controversy. The company's business model emphasizes developing inexpensive alternatives to off-patent medicines where single manufacturers charge excessive prices. With a portfolio that includes branded, generic, and compounded ophthalmic medications, Harrow serves healthcare providers and patients across the United States through its FDA-registered outsourcing facilities and nationwide distribution network.